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Attention-deﬁcit hyperactive disorder (ADHD) is the most commonly studied and diagnosed psychiatric
disorder in children. Methylphenidate (MPH, e.g., Ritalin) has been used to treat ADHD for over 50 years.
It is the most commonly prescribed treatment for ADHD, and in the past decade it was the drug most
commonly prescribed to teenagers. In addition, MPH has become one of the most widely abused drugs
on college campuses. In this study, we examined the effects of MPH on hippocampal synaptic plasticity,
which serves as a measurable quantiﬁcation of memory mechanisms. Field potentials were recorded
with permanently implanted electrodes in freely-moving mice to quantify MPH modulation of perforant
path synaptic transmission onto granule cells of the dentate gyrus. Our hypothesis was that MPH affects
hippocampal synaptic plasticity underlying learning because MPH boosts catecholamine signaling by
blocking the dopamine and norepinephrine transporters (DAT and NET respectively). In vitro hippo-
campal slice experiments indicated MPH enhances perforant path plasticity, and this MPH enhancement
arose from action via D1-type dopamine receptors and b-type adrenergic receptors. Similarly, MPH
boosted in vivo initiation of long-term potentiation (LTP). While there was an effect via both dopamine
and adrenergic receptors in vivo, LTP induction was more dependent on the MPH-induced action via D1-
type dopamine receptors. Under biologically reasonable experimental conditions, MPH enhances hip-
pocampal synaptic plasticity via catecholamine receptors.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Attention deﬁcit/hyperactivity disorder (ADHD) is a behavioral
disorder characterized by inattention, hyperactivity, and impul-
sivity. Although newer drugs have been developed, methylpheni-
date (MPH) is one of the most highly prescribed drugs for the
treatment of ADHD (Chai et al., 2012). MPH dose-dependently in-
creases extracellular dopamine (DA) and norepinephrine (NE)
indirectly by blocking the transporters, DAT and NET (Biederman
and Spencer, 1999; Kuczenski and Segal, 1997, 2002). Functionally,
MPH is remarkably similar to cocaine in both DAT blockade and
subjective “high” when administered by the same route (StoopsLtd. This is an open access article uet al., 2003; Volkow et al., 1995; Volkow and Swanson, 2003).
Human studies using PET imaging show that intravenous MPH
increases DA neurotransmission in the striatum (Volkow et al.,
2004), which is an earmark of addictive drugs (Di Chiara, 2002).
MPH increases hippocampal NE and DA in vivo (Kuczenski and
Segal, 2002; Weikop et al., 2007), both of which are known to
affect synaptic plasticity such as long-term depression (LTD) and
long-term potentiation (LTP) (Hopkins and Johnston, 1984; Hyman
et al., 2006; Izumi et al., 1992; Jones and Bonci, 2005; Kauer, 2004;
Lisman and Grace, 2005; Thomas et al., 1996). As well as inﬂuencing
hippocampal plasticity (Kulla and Manahan-Vaughan, 2000; Saji-
kumar and Frey, 2004; Tang and Dani, 2009), DA neurotransmission
also inﬂuences hippocampal-related function (Rossato et al., 2009).
These results are consistent with evidence indicating that addictive
drugs act upon synaptic plasticity mechanisms that normally un-
derlie learning and memory (Dani and Harris, 2005; Hyman et al.,nder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Ungless et al., 2004; Winder et al., 2002).
One of the most important pathways for the formation of
associative memory is the perforant path, which originates in the
entorhinal cortex and transmits convergent information from the
neocortex to the hippocampus (Deadwyler et al., 1979; Lavenex and
Amaral, 2000). The accumulated evidence supports that synaptic
plasticity along the perforant path is a substrate for memory
(Lynch, 2004; Martinez and Derrick, 1996; McHugh et al., 2008;
Rumpel et al., 2005), and the medial perforant path in particular
carries place and spatial information (Hargreaves et al., 2005) that
is important for drug associatedmemory. Both DA and NE release in
the hippocampus enhance LTP and learning, which establishes a
functional link between memory systems and the catecholamine-
releasing “reward” centers (Lisman and Grace, 2005; Moore and
Bloom, 1979). Recent work suggests that these two catecholamine
systems may be more interactive in the hippocampus than previ-
ously anticipated (Agnati et al., 1995; Borgkvist et al., 2012; Smith
and Greene, 2012). In this study, we examined MPH's inﬂuence
over perforant path synaptic plasticity owing to signaling via DA or
NE receptors.2. Materials and methods
2.1. Experimental procedures
All animal experiments were been carried out in accordance with the NIH guide
for the care and use of laboratory animals and according to protocols submitted to
the Institutional Animal Care and Use Committee at Baylor College of Medicine. All
efforts were made to minimize animal suffering, to reduce the number of animals
used, and to use alternatives to in vivo techniques when available.2.2. Slice preparation and perforated patch clamp recording
Hippocampal slices containing the dentate gyrus were prepared as previously
described (Zhang et al., 2010). Brieﬂy, C57BL/6 mice of either sex (24e30 day old)
were anesthetized via injection of a mixture of ketamine (42.8 mg/ml), xylazine
(8.6 mg/ml), and acepromazine (1.4 mg/ml). When the animal was deeply anes-
thetized, it was decapitated. Then the brain was rapidly removed and sliced with a
vibratome (Leica VT 1000S). Four horizontal brain slices (270 mm thick) were ﬁrst
recovered in a homemade chamber ﬁlled with low-calcium, high-magnesium arti-
ﬁcial cerebrospinal ﬂuid (ACSF) containing (in mM): 125 NaCl, 25 NaHCO3, 2.5 KCl,
1.25 NaH2PO4, 7 MgSO4, 0.5 CaCl2, and 25 D-(þ)-glucose continuously saturated
with 95% O2 and 5% CO2 at 32 C for 30 min and then maintained at room tem-
perature (22 ± 1 C) for at least 1 h until the recordings were begun.
The recordings were made with a 200B ampliﬁer (Axon Inst.) applied to a hip-
pocampal slice that was placed in a homemade recording chamber continuously
perfused with well oxygenated ACSF (1e2ml/min) containing (in mM): 125 NaCl, 25
NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 1 MgSO4, 2 CaCl2, 25 D-(þ)-glucose, maintained at
32e34 C by an automatic temperature controller (TC-324B, Warner Instrument
Corp, Hamden, CT). Picrotoxin (100 mM, SigmaeAldrich), a GABAA receptor antag-
onist, was routinely included in the ACSF. Patch-clamp recording electrodes
(3e4 MU) were ﬁlled with the following intracellular solution (in mM): 140 po-
tassium gluconate, 10 KCl, 10 HEPES, 5 MgCl2, (pH 7.2 with KOH) freshly supple-
mentedwith 200 mg/ml amphotericin B (SigmaeAldrich) (Yang et al., 2009). The rest
of the pipette solution containing amphotericin B was kept in a 4 C refrigerator and
was discarded after 6 h.
After achieving a gigaohm seal (>2 GU), a perforated whole-cell recording
conformation was obtained within 5e20 min as judged by gradual reduction of the
access resistance to <20 MU. Under current clamp, excitatory postsynaptic poten-
tials (EPSPs) were evoked by stimulation pulses generated by a stimulus isolator
(A365, WPI, FL) every 30 s via a stereotrode tungsten electrode (WPI, FL) placed at
the medial perforant pathway. A stable baseline was required for 10 min before
beginning the experiment by applying drugs or beginning the spike timing
dependent plasticity (STDP) protocol. In order to monitor the perforated patch
recording conditions, a small hyperpolarizing current (0.01 nA) was injected
(200 ms) through the recording pipette to measure input resistance. If the input
resistance changed by 30% or more, then the experiment was stopped and the data
were discarded. All drugs were bath applied for at least 15 min, and the STDP pro-
tocol (presynaptic stimulation followed by postsynaptic depolarization separated by
a 10-ms time interval) was delivered 60 times at 0.33 Hz in 3 min. The magnitude of
the synaptic plasticity change was deﬁned as the mean peak amplitude of 40
consecutive EPSPs taken 30e60 min after the end of STDP induction protocol
normalized by the average of the initial 20 consecutive EPSPs (i.e., baseline).2.3. Fast-scan cyclic voltammetry in striatal slices
Wild-type C57BL/6J male mice between the ages of 3 and 5 months were used
for these experiments. Animals were anesthetized via injection of a ketamine,
xylazine and acepromazine combination anesthetic. When the animal was deeply
anesthetized, it was decapitated, and the brain quickly dissected out. Horizontal
slices (300 mm) containing the dorsal striatum were incubated at 32 ± 0.5 C for
10 min and held at room temperature for 1 h. The slices were studied at 34 ± 1 C
in ACSF: 125 mM NaCl, 2.5 mM KCl, 1.3 mMMgCl2, 2.5 mM CaCl2, 1.25 mM Na2HPO3,
26 mM NaHCO3 and 10 mM glucose saturated with 95% O2 and 5% CO2.
Fast-Scan cyclic voltammetry was performed using homemade carbon-ﬁber
microelectrodes. The potential applied to the electrode was scanned linearly from
0 to 400 to 1000 to 400 to 0 mV at a rate of 300 mV/ms against a silver/silver
chloride reference. The tip of the carbon ﬁber recording electrode was centered
approximately 200 mm away from the tips of the bipolar stimulating electrode.
Voltammograms were sampled at 50 kHz and the background current was digitally
subtracted. An oxidation peak between 400 and 600 mV and a reduction peak
between 200 and 250 mV were used to identify the signal as a dopamine signal.
The peak oxidation currents for DA in each voltammogram were converted to a DA
concentration during a post experimental calibration of the carbon-ﬁber electrode
against solutions of 0.1e10 mM DA (Zhang et al., 2012, 2009, 2010).
The dorsal striatum was usually stimulated (1-ms duration, 0.6-mA constant
current) with a bipolar tungsten electrode with 120 s between stimulations to
ensure recovery of the DA signal. After recording stable DA release for 10 min in
ACSF, MPH was bath administered and allowed to equilibrate for 45 min before data
were collected for MPH induced changes in DA release. For some of the experiments,
stimulus trains were applied. When stimulation trains were applied, they combined
a tonic and phasic component. The tonic stimulation was given at 1.8 Hz, and the
phasic stimulation was given as 5 pulses at 20 Hz. The phasic stimulation matches
the average intraburst ﬁring frequency of approximately 20 Hz that has been
measured in vivo from rodents (Benoit-Marand et al., 2001; Hyland et al., 2002;
Zhang et al., 2009). The average frequency of the total stimulation train was 4 Hz,
which is consistent with the average baseline ﬁring rate of DA neurons in vivo. The
stimulation train was applied before and after bath administration of MPH (50 nM).
This MPH concentration is close to the peak serum concentrations observed
following moderate therapeutic oral dosages (Swanson and Volkow, 2003).
2.4. In vivo electrophysiology
2.4.1. Animal care and surgery
Adult male C57BL/6J mice (Jackson Laboratory), 3e4 months old, were used in
all of these experiments. For in vivo electrophysiology, the mice were housed indi-
vidually with food and water ad libitum in a temperature-controlled room
(23 ± 1 C) with a reversed 12 h artiﬁcial lightedark cycle (light on at 9 p.m.).
On day 0 mice were anesthetized with sodium pentobarbital (80 mg/kg, intra-
peritoneal injection, i.p., with additional 15 mg/kg supplements as necessary) and
secured into the stereotaxic apparatus. A concentric bipolar stimulating electrode
consisting of a tungsten wire placed inside a 30 gauge stainless steel tube was
positioned in the medial part of the perforant path (0.2 mm posterior and between
2.8 and 3.0 mm lateral of lambda, 1.0e1.3 mm below the dura). The recording
electrode (Teﬂon-coated tungstenwire, bare diameter 50 mm) attached to a stainless
steel guide tube (outer diameter 310 mm)was targeted ipsilaterally to the hilus of the
dentate gyrus (DG) (1.8e2.0 mm posterior, 1.4e1.6 mm lateral of bregma,
2.2e2.3 mm below the skull) (Franklin and Paxinos, 1997). The ﬁnal depth and
position of the electrodes were determined by judging the real-time electrophysi-
ological signal. A silver electrode placed contralaterally in the cortex served as the
recording reference and ground. Dental cement was used to anchor the electrodes
and the connecting device for chronic recordings. Mice were given at least 2 weeks
to recover before beginning the experimental recordings.
2.4.2. Handling, habituation, stimulation, and recording procedures
Beginning on day 10 post-surgery and continuing for 5 days, each animal
received 5 min of handling followed by administration of 0.3 ml saline (i.p.) in the
home cage in the experimental room both in the morning and afternoon. Then the
mice were individually habituated to the recording chamber: a Plexiglas cylinder
with bedding within a sound-reducing box (Med Associates, VT). At the same time
the mice were habituated to the recording headstage system. Mice received 1 h of
habituation daily for 4 consecutive days starting from day 11. Monophasic square
pulses (100 ms) were delivered to the perforant path (A360R, WPI, FL). Recorded
signals were ampliﬁed (100), ﬁltered (bandpass 0.1 Hze5 kHz), digitized at 10 kHz,
and stored on disk for off-line analysis. On day 15, an inputeoutput curve (I/O) was
generated. Single test stimuli were then delivered at 30 s intervals at an intensity
(35e100 mA) that evoked 40% of the maximal amplitude of the population spike.
In a typical experiment examining evoked synaptic responses in the perforant
path-dentate pathway, there were two or three counterbalanced sessions for each
mouse: e.g., saline, 5 mg/kg MPH, and 20 mg/kg MPH. Each data acquisition session
continued for 4 days. On day minus one (1d), the baseline amplitude of the pop-
ulation spike was examined for stability for 30 min. On 0d, another 30 min stable
baseline recording was required before administering saline, 5 mg/kg, or 20 mg/kg
MPH (i.p., 0.1 ml per 10 g body weight). The responses were usually monitored for
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for 5 h. In some cases, the baselines also were recorded between injection of drug or
saline and theta burst stimulation (TBS) to ensure stability (e.g., Fig. 4). In the ex-
periments for Fig. 4, after the baseline was recorded, mice were disconnected from
the recording ampliﬁer, given an injection of either saline or MPH, reconnected to
the recording ampliﬁer, and baseline recording continued for the 15 min before the
TBS was administered. However, during the multiple injections necessary for the
experiments of Figs. 5 and 6, we did not record during the manipulations to avoid
electrical noise. Themicewere left in the recording chamber, but unconnected to the
recording system in between the injections and TBS. The mice were reconnected
1e2 min prior to TBS administration. Baseline recordings were taken on 1d and 2d
after treatment to follow the overall stability of the recordings. I/O curves were
recorded systematically between sessions to verify the stability and the recovery
after the treatment of each session. Throughout the electrophysiological recording,
the mouse's behavior was video monitored, and the EEG derived from the dentate
gyrus recording also was displayed on an oscilloscope to ensure the absence ofFig. 1. MPH enhanced STDP in hippocampal slices. (A) A schematic diagram of a patch-
clamp recording (R) from a granule cell in a mouse dentate gyrus (DG) slice. A stim-
ulating electrode (S) was placed in the medial perforant path (mPP) originating in the
medial entorhinal cortex (EC). (B) An illustration of the STDP induction protocol with
Dt ¼ 10 ms, meaning the presynaptic stimulation preceded by 10 ms the postsynaptic
action potential (AC) ﬁring induced by current injection via the recording pipette. STDP
induction by the protocol in the presence of 500 nM MPH (C), 20 mM SCH-23390
(SCH) þ 500 nM MPH (D), 20 mM timolol (TIM) þ 500 nM MPH (E), and
SCH þ TIM þMPH (F), respectively. The open horizontal bar in each left panel indicates
the period of drug application, and the arrows indicate application of the 10 ms STPD
protocol. The right panel of the corresponding ﬁgures shows tabulated individual
plasticity values and averaged values of the magnitude of synaptic plasticity. (G) A
summary of the mean magnitude of STDP induced by the 10 ms protocol shown in CeF
and for control experiments. *p < 0.05 compared to the baseline, #p < 0.05 comparison
between the two groups indicated.electrical after discharges and to ensure themousewas in a “still-alert” state (Doyere
et al., 2003).
2.4.3. Theta burst stimulation
Theta burst stimulation (TBS) was designed to model the ﬁring patterns of
hippocampal neurons recorded during exploratory behavior in intact animals. A
single TBS train consisted of 6 individual 0.1 ms pulses in a 400 Hz burst with 6
bursts at 5 Hz per train. This train was repeated at an interval of 20 s to induce
different amounts of synaptic potentiation. A single train produced no change in
synaptic transmission, while 6 trains (a strong TBS protocol) consistently induced
LTP of the perforant path connection to dentate granule cells. We titrated the
strength of the TBS and found that 2 trains on average produced slight long-term
depression and did not induce signiﬁcant LTP on its own. This version of TBS was
used in all of the TBS experiments.
2.4.4. Drug administration and histology
All the drugs were from Sigma (St. Louis, MO). For i.p. injection, sodium pen-
tobarbitol, dl-threo-methylphenidate hydrochloride, R(þ)-SCH-23390 hydrochlo-
ride, and timolol maleate were dissolved in nonpyrogenic saline and adjusted for
injection volume of 0.1 ml per 10 g body weight. After all experimentation, the mice
were killed with an overdose of isoﬂurane. An anodal current (30 mA, 10 s) was
passed through the tungsten wire for identiﬁcation of the electrode placements.
Frozen 30 mm coronal sections were cut and stained with hematoxylin.
2.4.5. Data analysis
During the in vivo experiments, the amplitude of the population (pop) spike was
measured for each stimulus evoked postsynaptic response by calculating the depth
of the local ﬁeld potential. The pop spike amplitude was measured from the point
directly above the minimum of the local ﬁeld potential on an imaginary line
extending between the local maxima before and after the pop spike itself. The
calculated values from every ten consecutive pop spikes were averaged. The aver-
aged values before any drug treatmentwere normalized to 100%, and those averaged
values deﬁned the baseline. The mean baseline values were obtained during the
30 min of recording immediately before the ﬁrst drug treatment.
The in vivo data of Figs. 3e6 were collected in 3 continuous sections on day
0 (i.e., the treatment day). The baseline (30 min) collected before the treatments
began, the treatment section, and the post-treatment section (3 h). The baseline was
always normalized to 100%, and the value for synaptic transmission (i.e., the LTP or
LTD value) was calculated by averaging the data collected in the last hour of the post-
treatment section. To determine whether a treatment data set had an effect, we
ultimately compared the treatment group and its paired control group. The data
groups were analyzed with multi-way repeated measures analysis of variance
(ANOVA). In the cases where 3 or more groups were compared (i.e., Figs. 4e6), the
multi-way ANOVA indicated whether the groups were different. Then, a Tukey HSD
post-hoc test was performed to determine the relationship of signiﬁcant differences
between groups, and this process yielded the reported p value. That is, the process
indicated whether the treatment was different from its paired control, which also
indicated the induction of LTP or LTD.
3. Results
3.1. MPH enhanced STDP in hippocampal slices
EPSPs were evoked by stimulation pulses applied every 30 s via
an electrode placed in the medial perforant pathway and recorded
under current clamp through a perforated patch on dentate granule
cells (Fig. 1A). Fig. 1B indicates the timing of the STDP protocol that
was applied. The presynaptic stimulation occurred 10ms before the
postsynaptic depolarization. Postsynaptic current was injected to
cause the postsynaptic cell to ﬁre two action potentials at 100 Hz.
This pairing was repeated 60 times at 0.33 Hz over 3 min after
recording the baseline for 15 min to ensure stability of the
recording. EPSPs evoked by stimulation were recorded for 60 min
following the STDP pairing. The STDP stimulation protocol alone
did not produce consistent synaptic plasticity, with the average
being not signiﬁcantly different from baseline (94% ± 19%, n ¼ 7,
p ¼ 0.77; gray circle, Fig. 1G).
The literature indicates MPH doses for hippocampal slice ex-
periments ranging from about 50 nM to 300 mM (Dommett et al.,
2008; Ishimatsu et al., 2002). MPH has a higher afﬁnity for the
DAT (Ki ¼ 34 nM) than for the NET (Ki ¼ 339 nM) (Bymaster et al.,
2002; Pristupa et al., 1994), however, the median effective doses for
DAT and NET blockade are close (Hannestad et al., 2010; Volkow
Fig. 2. The MPH dose dependence for inﬂuencing DA release measured by fast-scan cyclic voltammetry. (A) Example DA traces before (0 MPH) and after bath administration of the
indicated concentration of MPH. The average DA responses peak magnitude (B) and dopamine signal area (C) are plotted against the MPH concentrations. (D) MPH (50 nM) in-
creases DA release. An example DA trace is shown before (black trace) and after MPH bath administration (gray trace). The bar graphs show that the average DA peak and area under
the DA curve increase after MPH administration. (E) MPH (50 nM) increases the phasic/tonic ratio of DA release. The phasic-to-tonic ratio increases following treatment with
50 nM MPH. The individual paired traces are averaged and plotted over each other. When treated with 50 nM MPH (larger amplitude gray trace), the tonic and phasic DA release
both increased. However, the phasic DA release increased more, and this result is reﬂected in the increased phasic-to-tonic ratios of the peak amplitudes and areas following MPH
application (bar graphs, right).
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increases in DA and NE concentrations in the prefrontal cortex
(Bymaster et al., 2002). Based on the literature and our voltam-
metry experiments below, we used a moderate concentration of
0.5 mM MPH, and found that MPH (0.5 mM) signiﬁcantly enhanced
LTP induced by the STDP protocol (154% ± 21% of baseline, n ¼ 7,
p ¼ 0.02, Fig. 1C; black circle, Fig. 1G).
SCH-23390, a D1/D5 receptor antagonist, reduced the STDP
enhancement so that it was no longer signiﬁcantly different from
baseline (SCH, Fig. 1D: 128% ± 48% of baseline, n ¼ 8, p ¼ 0.29;
black square, Fig. 1G). Timolol, a nonspeciﬁc NE b receptorantagonist also reduced the STDP enhancement so that it was no
longer signiﬁcant (TIM, Fig. 1E: 148% ± 46% of baseline, n ¼ 8,
p ¼ 0.17; black upward triangle, Fig. 1G). With a single antagonist,
the stimulation protocol for a given recording could produce LTP,
LTD, or no change, with the average being not signiﬁcantly
different from baseline (Fig. 1D and E, right panels). However,
when both antagonists (SCH-23390 and timolol) were applied
along with MPH before the STDP protocol, no change in synaptic
strength was observed, and individual recordings were much less
likely to vary greatly (Fig. 1F: 81% ± 15% of baseline, n¼ 6, p¼ 0.13;
black downward triangle, Fig. 1G).
Fig. 3. High dose of MPH induced LTP. (A) Anatomical track veriﬁcation of a recording electrode location in the dentate gyrus (dotted circle, left). The black dots show the range of
recording locations in the dentate gyrus (right). (B) Anatomical lesion of a stimulating electrode in the medial perforant path (arrow, left). The black dots show the range of
stimulation-site locations in the medial perforant path (right). (C) MPH-induced potentiation of the perforant path recorded in the DG (gray squares). The time course of each
procedure is across 4 days, from the day before (1d) until 2 days after (2d) the MPH administration. A 30 min baseline was obtained on 1d and conﬁrmed to be stable for 30 min
on day 0 (0d). Saline (black, n ¼ 5) or 20 mg/kg MPH (gray, n ¼ 5) was injected (i.p.) at 30 min on day 0 (vertical dashed line). The amplitudes of the population spike of the fEPSC are
plotted over time for 4 days (1d to 2d). Signiﬁcant LTP was measured for 20 mg/kg MPH on 0d (F(2,389) ¼ 7.8, p < 0.0005). The stability of the recordings and the return to baseline
are shown on 1d and 2d.
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protocol (black circle) signiﬁcantly enhanced STDP-induced LTP in
hippocampal slices compared to the baseline, compared to a con-
trol in which the STDP protocol was applied without MPH (light
gray circle), and compared to a control in which MPH was perfused
in the bath but no STDP stimulationwas applied (light gray square).
Adding either a DA D1/D5 receptor antagonist or a NE b receptor
antagonist reduced MPH-enhancement below the level of signiﬁ-
cance. Combining the two antagonists (black downward triangle)
potently blocked the increase in synaptic strength induced by MPH
during the STPD protocol.
3.2. MPH increased dopamine release in striatal slices
To better understand MPH's inﬂuence over DA release and MPH
dosing for our experiments, we used fast-scan cyclic voltammetry
(FSCV) to measure dynamic DA release from in vitro striatal slices,
which provide robust, measurable DA release. Our intent was to
ﬁnd the MPH dose that increases DA signaling without producing
an overly severe alteration in the DA signaling process. In that way,
we hoped to better model the more conservative dosing expected
in therapeutic situations. We used FSCV to obtain high ﬁdelity in-
formation on the time course of the evoked DA response. First we
completed a doseeresponse curve for concentrations of MPH
ranging from 1 nM to 300 mM (Fig. 2AeC), which covers the dose
range commonly used for in vitro hippocampal studies (Dommett
et al., 2008; Ishimatsu et al., 2002). The doseeresponse curve
showed an inverted U-shape curve. Up to 1 mMMPH, the DA release
is well behaved, but above that concentration the DA peak falls with
increasing MPH concentrations. Therefore, we used MPH concen-
trations well below 1 mM for the slice experiments, and we
considered doses in this range to be biologically reasonable.DA neurons discharge tonically at low frequencies that consist
mainly of individual action potentials (Grace and Bunney, 1984).
Periodically, DA neurons ﬁre phasic bursts that average near 20 Hz
in rodents (Hyland et al., 2002; Robinson et al., 2004; Zhang et al.,
2009). After bath application of MPH (50 nM), the DA release in the
dorsolateral striatum increased (Fig. 2D). For a single electrical
stimulus (1p), the peak DA concentration increased to
1.40 ± 0.15 mM from 0.99 ± 0.11 mM in the control (n ¼ 13,
p < 0.0002), and the total DA signal, measured as area under the
curve, increased to 0.89 ± 0.13 mM*s from 0.47 ± 0.07 mM*s in the
control (n ¼ 13, p < 0.005).
To examine the tonic and phasic components of DA release, a
tonic 1.8 Hz stimulationwas given before a phasic burst (5 pulses at
20 Hz). In the presence of MPH (50 nM), each DA response was
larger (Fig. 2E). Also the phasic-to-tonic ratios of the peak ampli-
tudes and areas were signiﬁcantly increased following MPH
application. The phasic/tonic ratio of the DA concentration peaks
increased to 3.07 ± 0.36 in MPH from 2.05 ± 0.26 in the control
solutions (n ¼ 11, p ¼ 0.009) and the phasic/tonic ratio of the area
under the DA curves increased to 5.91 ± 1.02 in MPH from
3.40 ± 0.59 in the control (n ¼ 11, p ¼ 0.014). Thus, MPH increased
phasic DA release more than it increased tonic DA release under
these conditions.
3.3. Behavioral observations deﬁned in vivo MPH dosing
We set out to ﬁnd an appropriate in vivo MPH dose that re-
capitulates some of the behavioral effects of cocaine, but not so
high as to induce stereotypy or impair performance on a behavioral
memory task. Increased locomotion and stereotypies are side ef-
fects of moderate to high therapeutic doses of MPH in humans. The
therapeutic range of MPH doses in humans has been suggested to
Fig. 4. Moderate dose of MPH enhanced TBS induced LTP. (A) Example traces compare
before (black trace) and after treatment (gray) trace for MPH (5 mg/kg) alone without
TBS, for saline with TBS, and for MPH (5 mg/kg) þ TBS. (B) Saline (gray, n ¼ 5) or 5 mg/
kg MPH (black, n ¼ 5) was injected 15 min before TBS stimulation was given. This
lower dose of MPH will not induce LTP alone (open circles, n ¼ 5). Each mouse received
2 series of TBS with saline or MPH in a counterbalanced manner over 2 weeks. An
injection of 5 mg/kg MPH followed by TBS results in signiﬁcant LTP of the population
spike amplitude (F(1,551) ¼ 176.17, p < 0.0001).
Fig. 6. Inhibiting NE b-receptors decreased but did not prevent MPH's effect. (A)
Systemic injection of a non-speciﬁc NE b-receptor antagonist, timolol, alone did not
affect synaptic transmission following the weak TBS (n ¼ 5). (B) Saline administered
before MPH and TBS (black, n ¼ 5) gave robust LTP, while timolol administered before
MPH and TBS (gray, n ¼ 7) decreased MPH's effect on the resulting synaptic trans-
mission, but LTP was not blocked. Treatments were counterbalanced and given at least
7 days apart for each mouse. Injection of timolol before the MPH/TBS LTP induction
protocol signiﬁcantly decreased the resulting synaptic transmission in the dentate
gyrus when compared to the saline control, (F(1,339) ¼ 252.4, p < 0.05).
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of administration and species differences in drug metabolism
signiﬁcantly affect plasma and brainMPH concentrations. Although
MPH has higher afﬁnity for the human DAT over the NET, 3 mg/kg
MPH injected i.p. in rats showed similar increases in DA and NE
concentrations in the prefrontal cortex, striatum, and nucleus
accumbens as a percentage of baseline (Bymaster et al., 2002).
Results also suggest that mice are less sensitive to MPH than rats,
and chronic injections of 3 mg/kg preferentially increased DA and
NE in the prefrontal cortex without affecting levels in the striatum
and without causing sensitization over 21 days of daily injections
(Koda et al., 2010). Guided by these data we performed open ﬁeld
experiments on several doses of MPH looking for increased loco-
motor behavior without stereotypies, deﬁned as repetitive turning
in tight circles or excessive self-grooming.
As a second test of a moderate dose of MPH, we ran mice
through a hippocampal dependent, delayed non-match to sample
T-maze task designed to test spatial working memory, a type of
memory that MPH is speciﬁcally known to enhance (Repantis et al.,Fig. 5. Inhibiting DA D1-type receptors blocked MPH's effect. (A) Systemic injection of
a D1/D5 receptor antagonist, SCH-23390, alone did not affect synaptic transmission
following the weak TBS (n ¼ 5). (B) Saline administered before MPH and TBS (black,
n ¼ 5) gave robust LTP, whereas SCH-23390 administered before MPH and TBS (gray,
n ¼ 5) did not show any synaptic transmission change (F(1,319) ¼ 248.19, p < 0.0001).
Treatments were counterbalanced and given at least 7 days apart for each mouse.2010; Wright and White, 2003). A boost in T-maze performance
should mean we have a moderate therapeutic dose, as indicated in
the literature by behavioral experiments in mice (Heredia et al.,
2013; Huang and Huang, 2012; Lloyd et al., 2013). A dose of
1 mg/kg did not signiﬁcantly increase locomotor behavior, while
5 mg/kg increased locomotor behavior without inducing stereo-
typy. We found, however, that a dose of 20 mg/kg did induce ste-
reotypy, andwe therefore labeled 20mg/kg a high dose of MPH. For
the remaining experiments we used 5 mg/kg as our medium dose
of MPH. After being thoroughly trained on the task, administration
of 5 mg/kg MPH (i.p.) signiﬁcantly increased correct arm choice in
the T-maze compared to mice that received saline (88% ± 7% after
MPH versus 69% ± 11% after saline as a control, p < 0.05, n ¼ 16 for
both groups, data not shown). This gave us our basis for dosing to
begin the in vivo electrophysiological experiments.3.4. MPH enhanced LTP in vivo
Field potentials evoked by stimulation of the medial perforant
path were recorded in the hilar region of the hippocampal dentate
gyrus from freely moving C57BL/6 mice (Fig. 3A, B). An example of
the lesion from a recording site is shown in Fig. 3A (left), and all the
recording sites in the dentate gyrus are indicated in Fig. 3A (right).
An example of the lesion from a stimulation site is shown in Fig. 3B
(arrow, left), and all the stimulation sites in the medial perforant
path are indicated in Fig. 3B (right). We focused on the medial
perforant path because it relays convergent information from the
neocortex that is rich in contextual, place, and spatial content
(Hargreaves et al., 2005), and evidence indicates that such infor-
mation is associated with the drug experience (Biala et al., 2005;
Kilts et al., 2001; Tang and Dani, 2009). Field recordings were
made from the hilus of the dentate gyrus to follow the synaptically
generated ﬁeld excitatory postsynaptic potential (fEPSP) and the
population (pop) spike, which corresponds to the synchronous
discharge of a large number of granule cells (Buzsaki and Czeh,
1981). The magnitudes of these components are directly related
to the number of neurons activated by the stimulus (Andersen et al.,
1971; Lomo, 1971). Synaptic transmission was quantiﬁed by
measuring the pop spike amplitude because the slope of the fEPSP
is often obscured in vivo by an increase in the pop spike that occurs
after synaptic potentiation induction in awake animals.
Two weeks after surgical implantation of the electrodes and
habituation to the recording situation, mice were treated with
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saline, 5, or 20 mg/kg MPH. We tested whether MPH alone would
induce any directional plasticity that could be measured by the pop
spike of the fEPSPs. Neither saline nor 5 mg/kg MPH affected syn-
aptic transmission: for saline, 104% ± 1.1%, n ¼ 3, p > 0.05 (Fig. 3C,
saline, black squares); for 5 mg/kg MPH (see Fig. 4B, open circles, to
simplify Fig. 3C). However, 20 mg/kg MPH induced long-term
synaptic potentiation (Fig. 3C, gray squares) as measured in the
pop spike amplitude 2 h after administration: 109% ± 1.1%, n ¼ 5,
p < 0.001 for 20 mg/kg.
To simulate a signal along the perforant path to the dentate
gyrus, we applied relatively weak theta burst stimulation (TBS) and
combined that TBS with MPH administration. Based on the in vitro
experiments (Fig. 1), we hypothesized that MPH should boost this
sub-threshold TBS paradigm to produce long-term potentiation
(LTP) owing to blockade of the NET and/or DAT (Kulla and
Manahan-Vaughan, 2000; Moore and Bloom, 1979; Rossato et al.,
2009; Sajikumar and Frey, 2004). A saline injection 15 min before
the standard theta burst stimulation resulted in slight long-term
depression (Fig. 4B, light gray circles, 93.1% ± 2.0% of baseline,
n ¼ 5, p ¼ 0.008). A moderate dose of MPH (5 mg/kg) alone did not
produce signiﬁcant synaptic change (Fig. 4B, open circles):
104% ± 1.1%, n ¼ 3, p > 0.05. However, when that dose was given
15 min before the standard TBS, it produced long lasting potenti-
ation of the perforant path to dentate gyrus pathway (Fig. 4B, black
circles): 131% ± 2.3%, n ¼ 5, p < 0.0001.
To determine whether primarily DA or NE receptors were
responsible for the MPH induced synaptic potentiation, we sys-
temically inhibited DA D1/D5 receptors (0.2mg/kg, i.p., SCH-23390)
or NE b receptors (10 or 20mg/kg, timolol). Injections of SCH-23390
(0.2 mg/kg, i.p) alone did not signiﬁcantly alter synaptic trans-
mission (Fig. 5A): 102.5% ± 2.8% of baseline, n ¼ 5, p > 0.05. In the
paired control experiments where saline (i.p.) preceded the MPH
administration, MPH induced a signiﬁcant potentiation over the
baseline (Fig. 5B, black squares): 164.2% ± 2.9% of baseline, n ¼ 5,
p < 0.0001. Systemic injection of SCH-23390 preceding MPH (5 mg/
kg) administration completely prevented synaptic potentiation
induced by MPH combined with TBS (Fig. 5B, gray squares):
100.1% ± 18.6% of baseline, n ¼ 5, p > 0.05. Injections of timolol (10
or 20 mg/kg, i.p.) alone did not signiﬁcantly alter synaptic trans-
mission (Fig. 6A): 103.2% ± 5.9% of baseline, n ¼ 5, p > 0.05. In the
paired control experiments where saline (i.p.) preceded MPH
administration, MPH followed by TBS induced a signiﬁcant poten-
tiation over baseline (Fig. 6B, black circles): 174% ± 13%, n ¼ 7,
p < 0.0001. Systemic injection of timolol decreased the change in
synaptic transmission induced by MPH preceding TBS, but signiﬁ-
cant LTP was still induced: 151% ± 3.4% of baseline, n ¼ 5,
p¼ 0.0037. The 3-way ANOVA and Tukey HSD post-hoc tests report
that all 3 groups are statistically different, indicating that when
timolol inhibits NE b receptors there is a difference in MPH's effect.
As always, the reported LTP value above was calculated for the last
hour of the 3 h time course after TBS administration (Fig. 6B). The
greatest difference caused by timolol occurs at earlier times during
the ﬁrst hour after TBS when inhibition of the NE b receptors by
timolol resulted in a stronger suppression of the early synaptic
potentiation: 136% ± 3.1%, n ¼ 5, p ¼ 0.0004.
4. Discussion
Methylphenidate (MPH) is widely used for the treatment of
ADHD to improve attention, learning, and memory. The main
mechanistic action of MPH is to inhibit DA and NE reuptake
transporters. Based on its action and on previous ﬁndings
(Dommett et al., 2008; Urban et al., 2013), we hypothesized that
MPH directly alters hippocampal long-term synaptic plasticity.Therefore, the inﬂuence of MPH over plasticity of the perforant
path to the dentate gyrus was examined. We focused on the medial
perforant path because it speciﬁcally carries place and spatial in-
formation (Hargreaves et al., 2005) that is important for associative
memory. The accumulated evidence also supports that synaptic
plasticity along this pathway is a contributing substrate of memory
(Lynch, 2004; Martinez and Derrick, 1996; McHugh et al., 2008;
Rumpel et al., 2005). Using in vitro slices we found that MPH en-
hances the induction of STDP. A STDP protocol that induced no net
synaptic change by itself would induce LTP when the stimulus
protocol was applied in the presence of MPH (0.5 mM). When either
the D1-type DA receptors were inhibited with SCH-23390 or the NE
b receptors were inhibited by timolol, the average LTP amplitude
induced by the MPH protocol was reduced (Fig. 1). In slices, it is
noteworthy that with either D1-type receptors or NE b receptors
inhibited there is still a trend toward potentiation, and there is
signiﬁcant scatter among the individual plasticity recordings
(Fig. 1D, E, right bar plots). When both sets of catecholamine re-
ceptors were inhibited, however, LTP induction by the STDP pro-
tocol was eliminated on average and for each individual
experiment (Fig. 1F, right bar plot). Chronic recordings from freely
moving mice showed that similar catecholamine mechanisms are
at play in vivo. Field potentials evoked by stimulation of the medial
perforant path were recorded in the hilar region of the dentate
gyrus (Tang and Dani, 2009). Weak theta burst stimulation (TBS)
that induced no synaptic change or slight LTD on its own, induced
LTP when applied in the presence of MPH (5 mg/kg). The LTP
induced by TBS þ MPH was reduced when NE b receptors were
inhibited by timolol (Fig. 6), but the LTP inductionwas absent when
D1-type DA receptors were inhibited with SCH-23390 (Fig. 5).
While both the in vitro and in vivo experiments suggest inﬂu-
ence by both catecholamines, the results are quantitatively
different. The in vitro experiments show inﬂuence by inhibiting
either the D1-type receptors or NE b receptors, but the strongest
inhibition of STDP occurred when both receptor types were
inhibited. The in vivo experiments show greater and complete in-
hibition of the MPH-inﬂuenced plasticity when the D1-type re-
ceptors were inhibited. These differences could arise from the
difference in the preparations. The in vitro slices were from 24 to 30
day old mice while the in vivo experiments were conducted on
young adult mice (3e4months old). Possibly more importantly, the
scatter among the individual experiments in vitro (Fig. 1D, E, right)
suggest that the individual placements of stimulation and
recording electrodes, coupled with the reduced slice preparation,
could produce more extremes in the local catecholamine signaling.
This variability appears less likely in the intact, in vivo situation
where mature, more consistent catecholamine signaling is present.
In that case, the actions of the receptors and the receptor inhibitors
may reﬂect the ﬁnal more reﬁned and consistent catecholamine
signaling into the dentate gyrus seen in the adult mice.
Evidence indicates that NET and DAT blockade inﬂuences indi-
vidual areas of the hippocampus differently (Hopkins and Johnston,
1988; Huang and Kandel, 1996; Ishihara et al., 1991; Lacaille and
Harley, 1985; Munro et al., 2001). In the hippocampal CA1 region
of rat slices, MPH boosted tetanic LTP based mainly on its ability to
block NETs because the NE b receptor inhibitor, timolol, blocked
MPH enhancement of tetanic LTP (Dommett et al., 2008). In our
experiments applied to the dentate gyrus, however, the DA D1-type
receptors and NE b receptors both seemed important during our
in vitro (relatively weak) STDP protocol applied to slices fromyoung
mice (24e30 d). Furthermore, the D1-type receptors seemed even
more important than the NE receptors during our in vivo TBS pro-
tocol in adult mice.
Previous reports showed mixed results for the ability of MPH to
increase DA and NE in slice preparations (Heal et al., 2008). We
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paradigm, suggesting that the STDP stimulation protocol can cause
variable DA and NE release from terminals in the dentate gyrus
slice. Furthermore, MPH signiﬁcantly increased these catechol-
amine signals to enhance synaptic plasticity. In vivo, TBS
enhancement byMPH in the dentate gyrus was more dependent on
the activity of DA receptors. Whether the DA driven enhancement
was due to endogenous DA release or preferential release of DA by
the TBS protocol itself is unknown. These differences in the results
that arise from different plasticity induction protocols applied to
different hippocampal locations are consistent with region-speciﬁc
forms of neuromodulation (Hopkins and Johnston, 1988; Huang
and Kandel, 1996; Ishihara et al., 1991; Lacaille and Harley, 1985;
Munro et al., 2001). Therefore, the cumulative results suggest that
MPH inﬂuences hippocampal plasticity owing to effects on both the
DA and NE systems.
Throughout these experiments we attempted to use stimulus
protocols and MPH doses that are reasonable. A TBS protocol was
used in vivo to mimic the theta mode of hippocampal ﬁring that is
observed during states of active, alert behavior in freely-moving
rodents (Hyman et al., 2003; Orr et al., 2001). That TBS protocol
only produced LTP after administration of MPH. Similarly, the STDP
protocol used for the in vitro experiments was mild. In addition, the
perforated-patch methodology, rather than the whole-cell conﬁg-
uration, was used for the in vitro recordings to preserve the intra-
cellular milieu. Unlike tetanic stimulation to induce synaptic
plasticity, STDP pairs a presynaptic stimulation followed by a
postsynaptic depolarization to mimic the biological case in which
the afferent activity drives a postsynaptic response in the target
area. The mild STDP protocol used for the in vitro experiments
induced synaptic plasticity (LTP) only in the presence of MPH
(0.5 mM). The doses of MPH arose from the literature, our voltam-
metry data, and our behavioral data. Based on our voltammetry
experiments, the DA release was well behaved up to 1 mM MPH,
which resulted in the largest peak evoked DA release. Therefore, we
used 0.5 mM MPH for the hippocampal slice experiments. This
concentration is higher than blood plasma levels in patients treated
for ADHD, which is usually in the range of 50e200 nM, but MPH
reaches higher concentrations in the brain than in the blood
(Hoffman and Lefkowitz, 1996). The MPH concentration (5 mg/kg)
used for the in vivo experiments with freely-moving mice had no
effect over in vivo synaptic transmission before the TBS was applied
(Fig. 4). This MPH dose (5 mg/kg) increased locomotor behavior
without inducing stereotypy, and this dose increased correct arm
choices in the delayed non-match to sample T-maze task. That task
is designed to test spatial working memory, which is a type of
memory that MPH is speciﬁcally known to enhance (Repantis et al.,
2010; Wright and White, 2003). Therefore, the 5 mg/kg dose of
MPH seems like a biologically appropriate concentration for the
behavioral tasks and in vivomeasurements of synaptic plasticity in
mice. Under these biologically reasonable experimental conditions,
MPH enhanced synaptic plasticity involving catecholamine
receptors.
Unpredicted rewards are known to produce brief burst ﬁring by
DA neurons (Schultz et al., 1997), and phasic bursts induce greater
extracellular DA release compared with tonic, single-spike ﬁring
activity (Floresco et al., 2003; Garris et al., 1994; Gonon, 1988;
Grace, 1991; Rice and Cragg, 2004; Zhang et al., 2009). Dopamine
neurons operate in these distinct tonic and phasic timescales to
differentiate behaviorally relevant information (Schultz, 2007). By
inhibiting DATs and NETs, MPH increases and lengthens the cate-
cholamine signal after release, which may share similarities to the
DA/NE signal after a long phasic burst. Our voltammetry results
showed that MPH enhanced the DA signaling from phasic bursts
even more than it enhanced the tonic signals. Likewise, MPH isexpected to enhance the size and length of adrenergic signaling.
Dopamine and adrenergic receptors are expressed in the hippo-
campus (Huang et al., 1992; Jurgens et al., 2005), and the cate-
cholamines have been shown to enhance synaptic plasticity via D1-
type DA receptors and b-type NE receptors (Lisman and Grace,
2005; Tang and Dani, 2009; Thomas et al., 1996). Our results sup-
port the importance of catecholamines in synaptic plasticity, and
the results indicate that MPH inﬂuences these synaptic processes.
Because the in vivo experiments were conducted on freely-moving
mice under biologically reasonable conditions, those results pro-
vide strong support for the importance of MPH acting via cate-
cholamines in the hippocampus.Acknowledgments
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